clinical trial · NCT04630002
Drug-drug Interaction (DDI) Study of GSK3640254 With Darunavir/Ritonavir (DRV/RTV) and Etravirine (ETR)
ViiV Healthcare·phase1·completed·n = 54
HIV InfectionsGSK3640254Darunavir/Ritonavir (DRV/RTV)Etravirine (ETR)
brief summary
This is an open-label, single-sequence, multiple-dose, 3 cohort study to investigate the effects of DRV/RTV and/or ETR on the pharmacokinetics (PK) of GSK3640254 and the effects of GSK3640254 on the PK of DRV/RTV and/or ETR. This study will aid in understanding these interactions and resulting changes in exposure (if any) when given in combination with GSK3640254.
started
Oct 28, 2020
primary completion
Oct 2, 2021
completion
Oct 2, 2021
last updated
Aug 29, 2024
official title
Open-Label, Single-Sequence Study to Evaluate the Effects of Darunavir/Ritonavir and/or Etravirine on the Pharmacokinetics of GSK3640254 and the Effects of GSK3640254 on the Pharmacokinetics of Darunavir/Ritonavir and/or Etravirine in Heathy Adults
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol